References
- The ADVANCE collaborative group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–72.
- Wu W, Li Q, Xia J, et al. Effects of the glucose-lowering rate on cTnI and hs-CRP serum levels in type 2 diabetics. Hum Immunol 2013;74:379–82.
- Wu W, Sun Z, Li Q, et al. Influence of the glucose-lowering rate on left ventricular function in patients with type 2 diabetes and coronary heart disease. J Diabetes Complications 2012;26:83–8.
- Miyao Y, Yasur H, Ogawe H, et al. Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am Heart J 1993;126:1299–303.
- Goruppi S, Patten RD, Force T, Kyriakis JM. Helix-loop-helix protein p8, a transcriptional regulator required for cardiomyocyte hypertrophy and cardiac fibroblast matrix metalloprotease induction. Mol Cell Biol 2007;27:993–1006.
- Kurremeyer KM, Michael LH, Baumgarten G, et al. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci USA 2000;97:5456–61.
- Mann DL, McMurray JV, Packer MK, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept World wide Evaluation (RENEWAL). Circulation 2004;109:1594–602.
- Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007;26:3279–90.
- Balmanno K, Cook SJ. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 2009;16:368–77.
- Ferrari R. The role of TNF in cardiovascular disease. Pharmacol Res 1999;40:97–105.